Related Experiment Video
Updated: Oct 17, 2025

09:49
Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury
Published on: January 20, 2023
3.4K
Mitigating Long-Term COVID-19 Consequences on Brain Health
Ryan C N D'Arcy1,2,3, Jagdeep K Sandhu4,5, Shawn Marshall6
1Centre for Neurology Studies, HealthTech Connex, Vancouver, BC, Canada.
Frontiers in Neurology
|October 14, 2021
Summary
The COVID-19 pandemic is linked to brain health issues like "brain fog," potentially caused by immune system injury. Clinical management should focus on nervous system resilience, drawing parallels with post-concussion syndrome.
Area of Science:
- Neurology
- Immunology
- Public Health
Background:
- COVID-19 is increasingly associated with neurological complications.
- Emerging evidence suggests immunological injury to the brain, manifesting as "brain fog."
- This neurological impact requires clinical management rather than solely medicalization.
Purpose of the Study:
- To explore the link between COVID-19 and brain health.
- To propose clinical management strategies for nervous system stress.
- To highlight the role of pre-morbid brain health in mitigating risks.
Main Methods:
- Review of emerging scientific literature on COVID-19 and neurological effects.
- Comparison with existing clinical frameworks for managing brain injuries and cognitive dysfunction.
- Emphasis on objective evaluation of cognitive changes.
Main Results:
- COVID-19 can lead to immunological brain injury and "brain fog."
- Clinical management should prioritize enhancing nervous system resilience.
- Digital health innovations are accelerating cognitive function assessment.
Conclusions:
- Managing the neurological impact of COVID-19 requires a focus on nervous system resilience.
- Pre-existing brain health is a significant factor in optimizing risk.
- Existing clinical frameworks for post-concussion syndrome offer valuable guidance.
Keywords:
SARS-CoV-2brain inflammationcognitioncoronavirusmental healthmoral injuryneuromodulationneuroplasticityMore Related Videos
Related Concept Videos
Long-term Depression
2.7K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.7K
Long-term Potentiation
56.4K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
56.4K
Cognitive Development During Adulthood
373
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
373
Alzheimer's Disease: Treatment
293
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
293

